Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr Surendera Tyagi, who will focus on the group’s non-injectables business and will become a member of Hikma’s executive committee.
He joins the pharma group from Fresenius Kabi, where he most recently led its US innovation and development centre.
Prior to this, he served as chief scientific officer for Sabur Pharma, an oncology company that was acquired by Fresenius in 2008.
Tyagi has also held various scientific and regulatory roles at Roche IGEN, Abbott/Hospita and Scwarz Pharma.
He said: “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share, and I look forward to accelerating their R&D efforts by advancing and expanding their pipeline.”